Antithromboembolic treatment after cardiac valve replacement

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Surgical Innovation

Background:

• Antithrombotic therapy is crucial for preventing thromboembolic complications following heart valve replacement surgery.
• Oral anticoagulants like warfarin and platelet inhibitors are standard, but their early postoperative use can be challenging.
• Thrombosis remains a risk in the immediate postoperative period when oral warfarin administration is not feasible.

Purpose of the Study:

• To evaluate the efficacy and safety of an alternative intravenous antithrombotic regimen in the early postoperative period after valve replacement.
• To assess the feasibility of using urokinase, low-dose heparin, and dipyridamole as a substitute for warfarin.
• To determine if this intravenous approach can prevent thrombosis without increasing bleeding risks.

Main Methods:

• A study involving 30 patients undergoing valve replacement surgery.
• Intravenous administration of urokinase, low-dose heparin, and dipyridamole during the early postoperative phase.
• Monitoring for thromboembolic events and adverse effects such as bleeding.

Main Results:

• No instances of thrombosis were observed in the patient cohort.
• No significant bleeding complications or marked bleeding tendencies were reported.
• The intravenous regimen was successfully administered to all 30 patients.

Conclusions:

• Intravenous urokinase, low-dose heparin, and dipyridamole serve as a safe and effective alternative to warfarin in the early postoperative period after valve replacement.
• This therapeutic strategy successfully prevents early postoperative thrombosis.
• The studied regimen offers a viable solution for patients unable to receive oral anticoagulation immediately after surgery.